Advertisement
UK markets closed
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • CRUDE OIL

    83.76
    +0.95 (+1.15%)
     
  • GOLD FUTURES

    2,344.40
    +6.00 (+0.26%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • Bitcoin GBP

    51,812.93
    +654.70 (+1.28%)
     
  • CMC Crypto 200

    1,397.55
    +14.98 (+1.08%)
     
  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

AstraZeneca’s Lynparza Continues to Dominate

AstraZeneca’s Lynparza Continues to Dominate

In the first quarter, Lynparza garnered revenue of $237 million for AstraZeneca (AZN), a YoY (year-over-year) rise of more than 105% driven mainly by its ongoing launch as a second-line maintenance therapy for ovarian cancer and as a therapy for germline BRCA-mutated metastatic breast cancer in the US and Japan.